RecruitingNCT05253560

Prodromal Parkinsonian Features in GBA1 Mutation Carriers


Sponsor

Shaare Zedek Medical Center

Enrollment

600 participants

Start Date

May 16, 2017

Study Type

OBSERVATIONAL

Conditions

Summary

Objective of the trial. To define a sub-population which is at increased risk of developing Parkinson, beyond the fact of carrying Gaucher; in this sub-population the investigators shall conduct a comprehensive evaluation that includes a variety of non-invasive tests, whose purpose is to evaluate the state of the pre- Parkinson's disease signs, signs which can appear, even twenty years before the appearance of the disease, and also to compare them to a group of diagnosed Gaucher patients and a group of healthy people who are not carriers of Gaucher disease. A group of those carriers will be available for trial or for treatment, if there will be a medicine for the prevention of the development of Parkinson, obtainable.


Eligibility

Min Age: 40 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying The investigators aim to identify prodromal PD in a cohort of carriers of Gaucher disease. for people with gaucher disease type 1 and healthy. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTThe investigators aim to identify prodromal PD in a cohort of carriers of Gaucher disease.

Tests to help identify prodromal PD in a cohort of carriers of Gaucher disease


Locations(1)

Michal Becker- Cohen

Jerusalem, Please Select..., Israel

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05253560


Related Trials